Cancer Sciences Specialization
The Cancer Sciences program offers laboratory-based training where both basic and translational medical research training is provided. Our program offers diverse research opportunities in molecular & cellular biology of cancer, clinical & translational oncology, novel therapeutics & diagnostics, and drug & biomarker discovery.
This specialization offers both thesis based Master of Science (MSc) and Doctoral (PhD) degrees.
Program Requirements:
On average, this program takes 2-3 years to complete and requires the following:
- 3 approved graduate level courses (9 units)
- 8 hours of academic integrity & ethics training
- 8 hours of professional development training and an Individual Development Plan
- Regular attendance at weekly Oncology 660/661 seminars
- Annual supervisory committee meetings
- Successful defense of MSc. thesis
On average, this program takes 4-6 years to complete and requires the following:
- 4 approved graduate level courses (12 units)
- 8 hours of academic integrity & ethics training
- 8 hours of professional development training and an Individual Development Plan
- Regular attendance at weekly Oncology 660/661 seminars
- Presentation of one formal seminar every year
- Annual supervisory committee meetings
- Completion of PhD. candidacy exam
- Successful defense of PhD. thesis
Departmental policies and procedures, on topics such as PhD candidacy exams, required courses, selecting Chairs for exams, and more can be found in our Oncology Graduate Student Handbook.
For information about general FGSR rules and regulations, such as thesis formatting, examining committee or supervisory committee composition, please refer to the FGSR Manual.
Principal Investigators & Supervisors
Not all of our staff supervise graduate students. Potential graduate students should contact investigators who's research interests align with their own and who state their willingness to supervise graduate students.
|
Dr. Kristi Baker |
Anti-tumor immunity; genetic instability; colorectal cancer |
||
|
Dr. Gordon Chan |
|
Mitotic cell cycle checkpoint and cancer |
|
|
Dr. YangXin Fu |
Signaling pathways and gene regulation in ovarian cancer and therapeutics |
||
|
Dr. Armin Gamper
|
DNA damage response: radiation biology |
||
|
Dr. Spencer Gibson |
Understanding the cell survival and cell death signaling in the lymphatic system and leukemias |
||
|
Dr. Roseline Godbout |
rgodbout@ualberta.ca |
Cancer as a developmental disease; retinoblastoma; brain tumors |
|
|
Dr. Michael Hendzel |
Nuclear components; DNA damage response; chromatin-based epigenetic mechanisms |
||
|
Dr. Ismail Ismail |
|
Targeting the DNA damage response in B cell malignancies |
|
|
Dr. John Lewis |
Translational prostate cancer research; nanoparticles, novel therapeutics, in vivo imaging |
||
|
Dr. Ralf Schirrmacher |
Radiopharmaceutical Chemistry, development of PET imaging agents for neuro- and cancer imaging, medicinal chemistry and drug development |
||
|
Dr. Alan Underhill |
Transcription factors in melanoma; gene regulation & epigenetics |
||
|
Dr. Michael Weinfeld |
|
Detection and repair of DNA damage |
|
|
Dr. Frank Wuest |
Nuclear medicine diagnosis and therapy of cancer, imaging biomarkers and radiotheranostics |